Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lorbrena
Pharma
Pfizer gains its fourth FDA approval for an ALK-positive tumors
Pfizer's Xalkori has been blessed to treat unresectable, recurrent or refractory inflammatory ALK-positive myofibroblastic tumors.
Kevin Dunleavy
Jul 15, 2022 10:49am
Pfizer's Xalkori follow-on, Lorbrena, snags front-line NSCLC nod
Mar 4, 2021 10:54am
Pfizer's Lorbrena blows by Xalkori in bid for front-line use
Sep 19, 2020 1:00pm
Pfizer's Lorbrena makes play for earlier lung cancer use
Aug 5, 2020 12:00pm
Pfizer's key to juggling 8 U.S. launches? Internal organization
Jul 19, 2019 12:12pm